Oppenheimer Upgrades Inspire Medical Systems (NYSE:INSP) to Outperform

by · The Markets Daily

Inspire Medical Systems (NYSE:INSP – Get Free Report) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on Tuesday, MarketBeat.com reports. The brokerage currently has a $85.00 price target on the stock. Oppenheimer’s target price points to a potential upside of 62.77% from the stock’s previous close.

INSP has been the subject of several other research reports. Royal Bank Of Canada lowered shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research note on Monday, June 15th. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Freedom Capital upgraded shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Evercore downgraded shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 price objective for the company. in a research report on Tuesday, June 23rd. Finally, Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $68.28.

Get Our Latest Research Report on Inspire Medical Systems

Inspire Medical Systems Stock Up 4.0%

Shares of NYSE:INSP opened at $52.22 on Tuesday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 11.63, a PEG ratio of 5.08 and a beta of 0.70. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03. The business’s 50 day moving average is $46.15 and its 200 day moving average is $55.17.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.Inspire Medical Systems’s revenue was down 7.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities research analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently made changes to their positions in INSP. Royal Bank of Canada grew its position in Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after buying an additional 4,528 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Inspire Medical Systems during the first quarter worth about $524,000. Goldman Sachs Group Inc. raised its position in Inspire Medical Systems by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after acquiring an additional 18,857 shares during the period. Marshall Wace LLP raised its position in Inspire Medical Systems by 3.8% in the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after acquiring an additional 577 shares during the period. Finally, Jump Financial LLC purchased a new position in Inspire Medical Systems in the second quarter valued at about $931,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

  • Positive Sentiment: Q2 earnings and revenue beat estimates. Inspire reported adjusted earnings of $0.14 per share, compared with the consensus estimate of a $0.24 loss, while revenue of $200.6 million exceeded expectations of approximately $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
  • Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Inspire now expects 2026 earnings of $1.05 to $1.45 per share, versus consensus of approximately $0.91. Revenue guidance of $835 million to $875 million brackets the $848.9 million analyst estimate. Inspire Medical Systems Announces Q2 Results and Raised Guidance
  • Positive Sentiment: Management presented a strategic growth plan. The earnings release and conference call emphasized initiatives intended to support future adoption and expansion, giving investors a more constructive outlook for the company’s obstructive sleep apnea treatment business. Inspire Medical Systems Q2 2026 Earnings Call Transcript
  • Neutral Sentiment: Growth remains mixed. Quarterly revenue declined 7.6% from the prior year, and EPS fell from $0.45 to $0.14, although both results were better than analysts expected. Investors are therefore likely to focus on whether the new growth initiatives can restore sustained revenue growth.
  • Negative Sentiment: The outlook still reflects execution risk. The revenue guidance range is relatively broad, and the midpoint is only modestly above current consensus, leaving the stock dependent on successful commercialization and broader procedure adoption.

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

Featured Articles